556 related articles for article (PubMed ID: 16774108)
41. Evaluation of the efficacy and safety of infliximab on psoriatic nails: an unblinded, nonrandomized, open-label study.
Rigopoulos D; Gregoriou S; Stratigos A; Larios G; Korfitis C; Papaioannou D; Antoniou C; Ioannides D
Br J Dermatol; 2008 Aug; 159(2):453-6. PubMed ID: 18565184
[TBL] [Abstract][Full Text] [Related]
42. Successful treatment of hand and foot psoriasis with infliximab.
Di Lernia V; Guareschi E
Dermatol Online J; 2010 Jul; 16(7):8. PubMed ID: 20673536
[TBL] [Abstract][Full Text] [Related]
43. Recalcitrant pustular psoriasis successfully treated with adalimumab.
Alvarez AC; RodrÃguez-Nevado I; De Argila D; Rubio FP; Rovira I; Torrelo A; Zambrano A
Pediatr Dermatol; 2011; 28(2):195-7. PubMed ID: 21504452
[TBL] [Abstract][Full Text] [Related]
44. [Personal experience with the use of infliximab].
Carretero G
Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():36-42. PubMed ID: 19080990
[TBL] [Abstract][Full Text] [Related]
45. Childhood generalized pustular psoriasis: longtime remission with combined infliximab and methotrexate treatment.
Skrabl-Baumgartner A; Weger W; Salmhofer W; Jahnel J
Pediatr Dermatol; 2015; 32(1):e13-4. PubMed ID: 25644044
[TBL] [Abstract][Full Text] [Related]
46. [Treatment of erythrodermic psoriasis with cyclosporin].
Manganoni AM; Giustina A; Zuccato F; Calzavara P; Pasolini G; Braga D; Gavazzoni R
G Ital Dermatol Venereol; 1988 Dec; 123(12):675-6. PubMed ID: 2978160
[No Abstract] [Full Text] [Related]
47. Clinical experience of ixekizumab in the treatment of patients with history of chronic erythrodermic psoriasis who failed secukinumab: a case series.
Lo Y; Tsai TF
Br J Dermatol; 2019 Nov; 181(5):1106-1107. PubMed ID: 31145806
[No Abstract] [Full Text] [Related]
48. [Clinical morphological parallels in the exudative form of psoriasis complicated by erythroderma and treated with corticosteroids].
Vedrova IN; Demidov AI
Vestn Dermatol Venerol; 1973 May; 47(5):54-7. PubMed ID: 4271158
[No Abstract] [Full Text] [Related]
49. Persistent expression of CD26/DPPIV after treatment with infliximab in psoriasis despite clinical improvement.
van Lingen RG; van Erp PE; Seyger MM; de Jong EM; de Boer-van Huizen RT; Driessen RJ; van de Kerkhof PC
Acta Derm Venereol; 2009; 89(5):518-20. PubMed ID: 19734982
[No Abstract] [Full Text] [Related]
50. Use of short-course class 1 topical glucocorticoid under occlusion for the rapid control of erythrodermic psoriasis.
Arbiser JL; Grossman K; Kaye E; Arndt KA
Arch Dermatol; 1994 Jun; 130(6):704-6. PubMed ID: 8002640
[No Abstract] [Full Text] [Related]
51. Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study.
Smith CH; Jackson K; Bashir SJ; Perez A; Chew AL; Powell AM; Wain M; Barker JN
Br J Dermatol; 2006 Jul; 155(1):160-9. PubMed ID: 16792769
[TBL] [Abstract][Full Text] [Related]
52. Excessive hair growth in a patient with psoriatic erythroderma following secukinumab administration.
Mashima E; Sawada Y; Yamaguchi T; Yoshioka H; Ohmori S; Haruyama S; Okada E; Nakamura M
Eur J Dermatol; 2018 Aug; 28(4):539-540. PubMed ID: 30325327
[No Abstract] [Full Text] [Related]
53. Infliximab and nephrotic syndrome.
Chin G; Luxton G; Harvey JM
Nephrol Dial Transplant; 2005 Dec; 20(12):2824-6. PubMed ID: 16204273
[TBL] [Abstract][Full Text] [Related]
54. A case of erythrodermic psoriasis successfully treated with ixekizumab.
Megna M; Gallo L; Balato N; Balato A
Dermatol Ther; 2019 Mar; 32(2):e12825. PubMed ID: 30650216
[TBL] [Abstract][Full Text] [Related]
55. Induction of lesional and circulating leukocyte apoptosis by infliximab in a patient with moderate to severe psoriasis.
Malaviya R; Sun Y; Tan JK; Magliocco M; Gottlieb AB
J Drugs Dermatol; 2006 Oct; 5(9):890-3. PubMed ID: 17039656
[TBL] [Abstract][Full Text] [Related]
56. Successful treatment of Von Zumbusch pustular psoriasis with infliximab.
Trent JT; Kerdel FA
J Cutan Med Surg; 2004; 8(4):224-8. PubMed ID: 16091999
[TBL] [Abstract][Full Text] [Related]
57. Rapid response to infliximab in severe pustular psoriasis, von Zumbusch type.
Newland MR; Weinstein A; Kerdel F
Int J Dermatol; 2002 Jul; 41(7):449-52. PubMed ID: 12121565
[TBL] [Abstract][Full Text] [Related]
58. Long-term control of recalcitrant psoriasis with combination infliximab and methotrexate.
Warren RB; Brown BC; Carmichael AJ; Griffiths CE
Clin Exp Dermatol; 2009 Apr; 34(3):415-6. PubMed ID: 19120390
[No Abstract] [Full Text] [Related]
59. The relationship between quality of life and skin clearance in moderate-to-severe psoriasis: lessons learnt from clinical trials with infliximab.
Reich K; Griffiths CE
Arch Dermatol Res; 2008 Nov; 300(10):537-44. PubMed ID: 18784934
[TBL] [Abstract][Full Text] [Related]
60. Erythrodermic psoriasis improved by panitumumab, but not bevacizumab.
Nishizawa A; Satoh T; Yokozeki H
Acta Derm Venereol; 2012 Jul; 92(4):360-1. PubMed ID: 22565356
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
